(Kingsport, TN) – Developing pharmaceuticals can be a risky business. It can be time and resource intensive, and most drugs don’t even make it past the first phase of clinical trials. But the ones that do, increase in value exponentially and have a much greater chance for market approval.
That’s why IPE, Inc. is celebrating the recent success of BCT303, its lead drug candidate to treat hypothyroidism, which completed Phase-One clinical trials at Georgetown University on August 3, 2012, two months ahead of schedule with positive results—none of which could have been possible without the help from some local angel investors.
“This was a real team effort,” says Eric Latham, Chief Executive Officer of IPE. “We brought together good science and business to accomplish this goal.”
BCT303 fixes two problems. Compared to the current branded drug in the market, it is designed to increase safety by delivering more predictive therapeutic levels in patients and improve stability, so it can last longer on the shelf. The hypothyroid market is worth more than $1 billion annually in the United States alone.
Now, BCT303 is ready for Phase-Two clinical trials and IPE is seeking further funding from local angel investors to continue developing this drug.
IPE, Inc. is a local, family-owned and operated, pharmaceutical drug discovery and development company with locations in Bristol, Virginia and Kingsport, Tennessee.
IPE’s branded, prescription drug division is based on four patents for platform technology. These patents have led to the discovery of drugs in the following therapeutic arenas: Central Nervous System, Oncology, Gastro-Intestinal, Endocrinology, Cardiology, Wound-Healing and Dermatology.
IPE’s mission is to discover and develop new technology and innovative products that improve health worldwide.
To learn more, visit www.ipeamerica.com.